Over the past several months, in conversations with pharmacy leaders, interprofessional colleagues, and national stakeholders, I have heard a message that continues to resonate with me:

Stories matter. Not as anecdotes alone. Not as a substitute for evidence. Stories as translation.

As pharmacists, we often describe ourselves as medication experts. This is true, and it matters. But I am increasingly convinced that medication expert is not the story that moves people. It is only the foundation. The more compelling story is what our expertise protects, what it prevents, and why it matters to patients, families, health care teams, and communities. Expertise is the input. Harm prevention is the story.

This distinction matters because many people outside the pharmacy profession experience our value not through lists of credentials, services, or knowledge domains but through patient care that becomes safer, clearer, more accessible, more reliable, or less likely to cause harm. They experience it when a confusing regimen finally makes sense, an unsafe dose is corrected, duplicate therapy is discontinued, a medication is made affordable, monitoring is implemented, or an adverse effect is recognized before it becomes an emergency. For clinical pharmacists, this is where our professional purpose resides: not simply in knowing medications, but also in using this knowledge to reduce preventable medication-related harm.

The challenge we face, however, is that much of this work remains invisible. When clinical pharmacists prevent harm, often nothing dramatic happens. The patient is not hospitalized. The ED visit does not occur. Bleeding events, hypoglycemic episodes, readmissions, treatment failures, and therapy abandonment are avoided. The patient simply continues on, safer than before. This invisibility is part of the paradox of our work, which is why the way we tell our story matters.

What Broader Pharmacy Conversations Are Teaching Me

This lesson has become clearer for me in national pharmacy conversations in which ACCP participates alongside other organizations and stakeholders. The topics are often expansive: health IT interoperability, digital infrastructure, rural health transformation, workforce dynamics, payment mechanisms, public health policies, care access, technology applications, and emerging care models. At first glance, these may sound like policy- or systems-based topics. But beneath each of them is a human question: Can the health care system see what patients need before harm occurs?

For clinical pharmacists, this question is inseparable from the patient’s medication story and is more than a medication list. A medication list only tells us what is currently prescribed. A medication story tells us whether therapy is safe, effective, accessible, understood, monitored, and still appropriate. It includes what changed after a hospitalization, what the patient can afford, what the patient is actually taking, what monitoring is overdue, what adverse effects may be emerging, what instructions are unclear, and what risk still needs attention. When this story does not extend across care settings, risk emerges.

This is why health IT interoperability should not be framed only as a technology issue. It is also a patient safety issue. TEFCA, the Trusted Exchange Framework and Common Agreement, operates as a nationwide framework for health information sharing intended to reduce barriers to electronic health information exchange among health care providers, patients, public health agencies, and payers.¹ This may sound technical, but it becomes meaningful when it helps the right information reach the right person or entity at the right time.

Medication decisions depend on context. A prescription without an indication may be misunderstood. A dose without renal function assessment may be unsafe. A refill gap without an understanding of the affordability context may be mislabeled as nonadherence. A discharge medication list without verification of patient understanding may create confusion. A clinical pharmacist intervention that cannot be seen by the rest of the care team may protect the patient once but fail to change the system that allowed an error to occur. This is not just an information gap. It is a harm-prevention gap.

Rural Health Transformation Makes the Stakes Visible

The national focus on rural health transformation brings this issue into sharper focus. CMS describes the Rural Health Transformation Program as a $50 billion allocation of funds to approved states over 5 years, with $10 billion available each fiscal year from 2026 through 2030.² CMS has also described the program as supporting expanded access to care in rural communities, strengthening the rural health workforce, modernizing rural facilities and technology, and supporting innovative models that bring dependable care closer to home.³ This creates an important opening for clinical pharmacy. It also creates an important responsibility.

Rural health transformation cannot only be about hospitals, broadband access, telehealth platforms, dashboards, or payment models. These may be necessary facilitators, but they are not sufficient on their own. Transformation must also address what happens in the spaces between formal care encounters. Clinical pharmacists, especially those practicing in community pharmacies, often work in the spaces between hospital discharge and follow-up—the gaps that exist among a prescription written and a medication taken, a telehealth visit and the patient’s daily medication routine, a therapeutic plan and the patient’s ability to afford it, a new diagnosis and the monitoring needed to use treatment safely—between confusion and harm.

In rural communities, these spaces are likely to be wider. A patient may leave a hospital miles away with a changed regimen and limited follow-up. A patient may receive care through telehealth but rely on a local pharmacy to understand and obtain the prescribed therapy. A patient with a chronic illness may face transportation barriers, health care workforce shortages, affordability challenges, medication shortages, limited monitoring access, or fragmented communication across care settings.

In these moments, pharmacists do more than dispense medications. They detect risk, interpret medication information, recognize when something does not fit, identify access barriers, clarify instructions, support adherence, monitor for effectiveness and toxicity, and help patients understand what to do next. This is harm prevention.

But accessibility alone is not transformation. A pharmacist’s accessibility becomes transformative only when the pharmacist’s observations, interventions, and concerns can be documented, exchanged, acted on, and valued by the broader care system.

From Data to Meaning

Another lesson I am learning from these conversations is that data and stories are not in opposition to one another—they are complementary. Data can show patterns, gaps, and opportunities. Stories explain why these gaps matter.

A dashboard may show that a patient is overdue for monitoring, but a clinical pharmacist can uncover why: transportation, cost, misunderstanding, adverse effects, limited access to care, or a regimen that no longer fits the patient’s lifestyle. A shared record may show that a medication was prescribed, but a clinical pharmacist can help determine whether the patient obtained it, understood it, and was able to use it safely. This is the bridge pharmacy can offer. We translate medication data into patient-specific meaning and patient stories into systems-based lessons.

Of course, evidence matters and we should continue to use it. But evidence alone does not always help others understand what medication harm prevention looks like in the life of a patient, the workflow of a care team, or the design of a safer system. This is where storytelling becomes strategy.

The Stories We Need Now

In an earlier column, I encouraged ACCP members to share the resources, models, tools, and examples they are using to improve medication safety, patient safety, and health care quality. I still believe this sharing is essential. But what I am learning through broader conversations is that our stories must do more than describe pharmacist activity. They must be translated into pharmacist value. They cannot simply celebrate our work. They must help others understand why the work matters and what should change because of it.

A stronger story does not begin with “A pharmacist reviewed the medication list.” It begins with “A patient was at risk of harm because…” A stronger story does not stop with “The pharmacist made a recommendation.” It continues with “That recommendation prevented…” And a stronger story does not end with “The team accepted the intervention.” It asks, “What would need to change so that this kind of prevention occurs reliably, not just when a pharmacist happens to be present?” This is where storytelling becomes strategy. A medication harm-prevention story should:

1. Begin with the risk, not the role. The role matters more when the risk is clear. Was the patient at risk of bleeding, hypoglycemia, kidney injury, treatment failure, uncontrolled symptoms, readmission, confusion, or not receiving needed therapy? Begin with what was at stake.
2. Make the invisible visible. Much of our best work prevents something from happening: adverse drug events, ED visits, readmissions, loss of trust, therapy abandonment. The story has to help others see the harm that did not occur because a pharmacist intervened.
3. Connect the action to the patient. It is not enough to say a recommendation was accepted. What changed for the patient? Was a dose corrected, duplicate therapy discontinued, a monitoring plan created, an affordability barrier resolved, a discharge plan clarified, therapy made safer, more effective, more accessible, or more understandable?
4. Identify the system lesson. The best stories do not end with individual excellence. They reveal what the system needs to learn. Was information missing? Did data fail to travel? Was the pharmacist’s intervention invisible to the rest of the care team? Did the payment model fail to recognize the work? Did a rural access gap make the pharmacist’s role essential?
5. Tell the story in language others can repeat. “Medication optimization” may be accurate, but “we prevented harm” is clearer. “Comprehensive medication management” may describe the service, but “we helped ensure this patient’s medicines would help rather than harm” explains the purpose. If others cannot repeat our value, they cannot carry it forward.

The Call to Action

So, my ask is evolving. Although I am still asking ACCP members to share examples of the resources, practices, and models that improve medication safety, patient safety, and health care quality, I am also asking that we tell these stories differently.

• Begin with the risk.
• Describe the harm prevented.
• Identify the system gap.
• State what should change.
• Use understandable, impactful language.

Wherever you practice, teach, lead, investigate, or serve, there is a harm-prevention story to tell. It may be a patient care story, research story, education story, quality improvement story, advocacy story, public health story, workforce story, or systems story. It may come from a bedside decision, clinic encounter, transition of care, stewardship initiative, deprescribing conversation, pharmacogenomics consult, medication access intervention, clinical decision support tool, learner activity, population health dashboard, policy change, or community partnership. The setting matters less than the lesson:

• What risk was present?
• What did the pharmacist see, know, ask, connect, or anticipate that changed the outcome?
• What harm was prevented or made less likely?
• What gap in the system did the story reveal?
• What changes are needed to make this kind of prevention reliable, visible, and expected?

These are the kinds of stories that can move systems. They can inform rural health transformation, shape interoperability conversations, guide payment reform, influence quality measurement, strengthen education and training, help policymakers understand why medication harm prevention is not optional, help patients and families understand what clinical pharmacists do and why our presence matters.

The next chapter of clinical pharmacy will be shaped by technology, data, payment, policy, workforce, science, and public expectations. But these forces alone will not elucidate our value. We must describe it clearly enough that others can see it, repeat it, build it into systems, and expect it as an essential component of safe care.

We are medication experts. But this is not where the story ends. Our story is what this expertise prevents.

And if we tell the story well—with evidence as well as clarity, humanity, and purpose—we can help ensure medication harm prevention is not invisible, accidental, or dependent on chance. We can help make it expected, measurable, and part of the infrastructure of care. This is how stories move systems. This is how we write the next chapter.

References

1. Office of the National Coordinator for Health Information Technology. Trusted Exchange Framework and Common Agreement (TEFCA). Accessed July 8, 2026. https://healthit.gov/policy/tefca/
2. Centers for Medicare & Medicaid Services. Rural Health Transformation (RHT) Program. Accessed July 8, 2026. https://www.cms.gov/initiatives/rural-health-transformation-rht-program/overview
3. Centers for Medicare & Medicaid Services. CMS announces $50 billion in awards to strengthen rural health in all 50 states. Published December 29, 2025. Accessed July 8, 2026. https://www.cms.gov/newsroom/press-releases/cms-announces-50-billion-awards-strengthen-rural-health-all-50-states